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BACKGROUND: The use of minimally invasive ablative therapies in localised prostate cancer offer potential for a middle ground between
active surveillance and radical therapy.
METHODS: An analysis of men with organ-confined prostate cancer treated with transrectal whole-gland HIFU (Sonablate 500)
between 1 February 2005 and 15 May 2007 was carried out in two centres. Outcome data (side-effects using validated patient
questionnaires, biochemical, histology) were evaluated.
RESULTS: A total of 172 men were treated under general anaesthetic as day-case procedures with 78% discharged a mean 5h after
treatment. Mean follow-up was 346 days (range 135–759 days). Urethral stricture was significantly lower in those with suprapubic
catheter compared with urethral catheters (19.4 vs 40.4%, P¼0.005). Antibiotics were given to 23.8% of patients for presumed
urinary tract infection and the rate of epididymitis was 7.6%. Potency was maintained in 70% by 12 months, whereas mild stress
urinary incontinence (no pads) was reported in 7.0% (12 out of 172) with a further 0.6% (1 out of 172) requiring pads. There was no
rectal toxicity and no recto-urethral fistulae. In all, 78.3% achieved a PSA nadir p0.5mgml
 1 at 12 months, with 57.8% achieving
p0.2mgml
 1. Then, 8 out of 13 were retreated with HIFU, one had salvage external beam radiotherapy and four chose active
surveillance for small-volume low-risk disease. Overall, there was no evidence of disease (PSA o0.5mgml
 1 or negative biopsy if
nadir not achieved) after one HIFU session in 92.4% (159 out of 172) of patients.
CONCLUSION: HIFU is a minimally invasive, day-case ablative technique that can achieve good biochemical outcomes in the short term
with minimal urinary incontinence and acceptable levels of erectile dysfunction. Long-term outcome needs further evaluation and the
inception of an international registry for cases treated using HIFU will significantly aid this health technology assessment.
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Men diagnosed with localised prostate cancer have to choose
between active surveillance or radical therapy in the form of
prostatectomy or radiotherapy (Bill-Axelson et al, 2005). Choosing
between these extremes of care is not easy, as radical treatments
come with a significant risk of morbidity (Zeliadt et al, 2006; Wilt
et al, 2008). In contrast, surveillance strategies confer minimal
treatment-related harms, but carry potential psychological burden
and delayed radical therapy in up to one-third of the patients as a
result of disease progression (van As and Parker, 2007). Ablative
therapies have the potential to offer a middle ground between these
extremes. They may confer different patterns of toxicity compared
with standard radical therapies and at the same time may offer
greater freedom from progression than that from surveillance
strategies. A number of platforms – cryosurgery, high-intensity-
focused ultrasound (HIFU), radiofrequency ablation and photo-
dynamic therapy – are in various stages of evolution, evaluation
and diffusion into clinical practise.
In this paper, we report our early experience with HIFU.
HIFU was evaluated following UK’s National Institute of
Clinical Excellence (NICE) guidance issued in 2005 stating they
‘y support the use of this procedure for the treatment of prostate
cancer’ but with the caveat that ‘y audit should address clinical
outcomes, long-term survival and indications for treatment’ (NICE
Guideline on High-Intensity Focused Ultrasound Therapy for
Prostate Cancer, 2005). In line with this request, we present our
data on the use of HIFU in treating men with prostate cancer. We
have adhered to Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) recommendations which are
appropriate in this setting (Vandenbroucke et al, 2007).
BACKGROUND
HIFU relies on the physical properties of ultrasound, which allow
it to be brought into a tight focus either using an acoustic lens,
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sbowl-shaped transducer or electronic-phased array. When the
energy density at the focus is sufficiently high, tissue damage
occurs through coagulative necrosis. The acoustic focal volume
of a single exposure is typically 10mm long by 1–2mm wide,
so larger ablative volumes are created by placing overlapping
lesions next to each other. There are two commercially available
transrectal devices, the Ablatherm (Edap-Technomed, Lyon,
France) and Sonablate 500 (Focus Surgery, Indianapolis, IN,
USA). The Sonablate 500 system’s treatment planning, execution
and monitoring are controlled using an interface which allows the
surgeon to target the area of treatment, adjust the focal length of
the transducer and alter the power delivered to each focal zone
(Illing et al, 2006).
METHODS
Men who did not wish to, or were unable to undergo either
surgery or radiotherapy for treatment of prostate cancer, and were
either not suitable or had rejected surveillance were offered
HIFU. These men were treated in two centres (Princess Grace
Hospital, London and University College London Hospital NHS
Foundation Trust), during the period 1 February 2005 to 15 May
2007, using the Sonablate 500 device. Each man was counselled
fully as to his treatment options and specifically told that HIFU
was not standard care and that outcomes were limited to short-
or medium-term follow-up from case series conducted in
France, Germany or Japan. In addition, they were made aware of
the reported frequency of side-effects. Men with specific contra-
indications to HIFU were excluded. These were a prostate
volume greater than 40ml (or a maximum anterior–posterior
height greater than 40mm), any focus of calcification (410mm
in maximum diameter), significant anorectal disease preventing
probe insertion (e.g., previous haemorrhoidectomy) or
carrying increased risk of fistulae (e.g., Crohn’s disease). To
achieve these size restrictions, some were pretreated with low-
dose antiandrogen monotherapy for 3 months to reduce the
gland size.
During the period in question some of our practises altered. At
the outset, all men were fitted with a urethral catheter for 7–10
days, but after consultation held in international user group
meetings it was agreed that suprapubic catheters might result in
earlier voiding, fewer urinary infections and lower rates of
stricture. As most were tertiary referrals and lived some distance
away, all men were taught clean intermittent self-catheterisation,
so that they were able to self-manage poor flow or pending
retention of urine due to passage of debris. Follow-up after
treatment mirrored the regimen used after standard radical
therapies: serum PSA measurements at 6 weeks, and then every
3 months for the first year, and every 6 months for subsequent
years of follow-up. Patients at one of the centres completed pre-
and post-treatment validated questionnaires (International Pros-
tate Symptom Score [IPSS], International Index of Erectile
Function-15 (IIEF-15)). Incontinence data were collected from
patient reported outcomes on leakage and pad usage. The IIEF-15
data was analysed in two ways. First, we selected a question that is
accepted as a good indicator of erectile function (Burnett et al,
2007), ‘When you had erections with sexual stimulation, how often
were your erections hard enough for penetration?’. We defined
potency as scoring either 2 and above or 3 and above on a scale of
0–5: (0) No sexual activity, (1) Almost never/never, (2) A few
times (much less than half the time), (3) Sometimes (about half the
time), (4) Most times (much more than half the time), (5) Almost
always/always. The cohort of 49 completing 12 months of
questionnaires with preoperative data were included in the
analysis as it provided the most reasonable balance between
absolute numbers and duration of follow up. The second form of
analysis for erectile function involved a repeated measures analysis
comparing mean IIEF-15 score obtained before therapy to that
measured at key intervals on follow-up.
Patients not achieving a PSA nadir of p0.5ngml
 1 or those
with PSA o0.5ngml
 1 and two consecutive increases in PSA were
advised to have a transrectal prostate biopsy. Patients were
stratified using 1998 D’Amico risk categories (D’Amico et al,
1998).
RESULTS
Baseline data
In all, 172 treated with the Sonablate 500 HIFU device for primary
prostate adenocarcinoma (pT3bN0M0) were identified. None had
pre-HIFU transurethral resection of prostate. The mean age was
64.1 years (±s.d. 8.3) with a mean follow-up of 346 days (±s.d.
237, range 135–759). Patients were risk stratified in the 136 men in
which this was possible. Here, 27.8% (38 out of 136), 37.5% (51 out
of 136) and 34.6% (47 out of 136) were in the low-, intermediate-
and high-risk categories. Thirty six patients did not have complete
data for risk stratification but for completeness their data was also
analysed (Table 1). Thirteen patients were lost to follow-up.
However, there was no significant difference in the baseline PSA
(10.0 vs 8.4, ANOVA P¼0.522), Gleason score (mean 6.3 vs 6.5,
ANOVA P¼0.449) and T-stage (ANOVA P¼0.666). Around 29%
Table 1 Baseline demographic data for localised Prostate Cancer treated
with HIFU
Number 172
Age, years (median, s.d., range) 64.1 (s.d. 8.3) (47–88)
Hormones
a 49 (28.5%)
No. %
Pre-HIFU PSA (pre-cytoreduction) (ngml
 1)
0–4.0 24 15.9
4.1–10.0 85 56.3
10.1–20.0 37 24.5
420.0 5 3.3
Unavailable 21 12.2
Gleason
p6 89 54.6
¼7 64 39.3
47 10 6.1
Unavailable 9 5.2
Stage
T1c 48 33.1
T2a 25 17.2
T2b 29 20.0
T2c 17 11.7
T3a 23 15.9
T3b 3 2.1
Unavailable 27 15.7
Risk categories
b
Low 38 27.9
Intermediate 51 37.5
High 47 34.6
Unavailable 36 20.9
aAll cytoreduced with anti-androgen and 5-a reductase inhibitor for 3 months.
bD’amico risk categories were defined according to the 1998 criteria as follows: Low:
PSA p10ngml
 1 and Gleason p6 and Stage pT2a (For low risk, all these
parameters must be met); Intermediate: PSA 10.1–20ngml
 1 or Gleason p7o r
Stage T2b (For intermediate, any one of these or a combination of all of these equals
intermediate, provided no high-risk parameters are present); High: PSA 420ngml
 1
or Gleason 8–10 or Stage XT2c (For high risk, the presence of any of these
parameters equals high risk).
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s(50 out of 172) of the patients were on 3 months bicalutamide
(50mg once daily) and 5-a reductase inhibitors (dutasteride or
finasteride) before HIFU to reduce gland size. Hormones were
stopped on the day of treatment. All were treated under general
anaesthetic in a single session. Median hospital stay was 5h (range
3–24 hours) and reasons for overnight stay (22%) were
haematuria (no transfusion), co-morbidity (not fit for day-case
surgery), lack of home care and side-effects from general
anaesthesia.
Morbidity
Mean catheterisation time was 13.9 days (±s.d. 8.3). In all, 30.2%
of men required interventions for either a stricture or necrotic
tissue within the prostate cavity. Mode of catheterisation appeared
to make a difference to the likelihood of experiencing either a
stricture or having retained necrotic tissue. Of those with a
suprapubic catheter developed this problem compared to 40.4% in
those with a urethral catheter (P¼0.005, w
2 test). Strictures or
retained necrotic tissue were treated in the following manner: local
anaesthetic dilatation, 15.7% (27 out of 52); general anaesthetic
dilatation and/or resection, 18.0% (31 out of 52); bladder neck
incision, 10.5% (18 out of 52) (Table 2). Any degree of urine
leakage was reported regardless as to whether it required pads or a
change in underwear or not. Grade 1 stress urinary incontinence
(no pads) occurred in 7.6% (13 out of 172) of the patients with
0.6% (1 out of 172) of the patients suffering grade 3 stress urinary
incontinence requiring an artificial urinary sphincter. None of the
men required security pads. IPSS score significantly deteriorated at
3 and 6 months but returned to baseline at 9 and 12 months. Scores
at baseline, 3, 6, 9, and 12 months were 6.7 (±s.d. 5.8), 12.0 (±8.6,
Po0.01), 9.2 (±8.0, P¼0.02), 7.9 (±7.5, P¼0.32), and 7.8 (±s.d.
7.3, P¼0.42) (P-values quoted are comparative to baseline).
A degree of dysuria was noted in all men for a week following
treatment in those fitted with a suprapubic catheter or following
catheter removal in those fitted with a urethral catheter. Around
23.8% of patients received antibiotics at some point during the
period of follow-up for a presumed urinary tract infection. In all,
17.9% (12 out of 67) were prescribed antibiotics in the group with
a suprapubic catheter compared to 24.4% (23 out of 94) of those
with a urethral catheter. Epididymitis occurred in 7.6% (13 out of
172) of patients. Eight of these had a urethral catheter, although
the overall percentage with epididymitis in the group with a
urethral catheter was 8.5% (8 out of 94) and 7.5% (5 out of 67) in
the group with a suprapubic catheter.
About 94 men completed the IIEF-15 questionnaire preopera-
tively. All were offered phosphodiesterase type 5 inhibitors (either
sildenafil or tadalafil). It was not possible to determine from the
case notes the number using medication to assist in getting or
maintaining erections. The number completing post-treatment
questionnaires at 3, 6, 9, and 12 months after treatment were 92,
77, 51, and 34, respectively. 24 out of 51 were deemed potent
preoperatively using question 2 threshold of 2 and above. At 3, 6, 9
and 12 months post-HIFU, 37.5% (9 out of 24), 45.8% (11 out of
24), 58.3% (14 out of 24) and 66.7% (16 out of 24) were potent,
respectively. When using a threshold value of 3 or more, 12 out of
51 were deemed potent prior to HIFU and 41.7% (5 out of 12),
58.3% (7 out of 12), 66.7% (8 out of 12) and 66.7% (8 out of 12)
Table 2 Operative factors and morbidity outcome for localised prostate cancer treated with HIFU
General Anaesthesia 172 (100%)
Mean follow-up (days) (s.d., range) 346 (237, 135–759)
Catheter type
Urethral 58.4% (94)
Suprapubic 41.6% (67)
Not known 6.4% (11)
Catheterisation time, days (mean, s.d.) 13.9 (8.3)
No. of patients requiring intervention for stricture/necrotic tissue 30.2% (52)
Dilatation for stricture (local anaesthesia) 15.7% (27)
Intervention for necrotic tissue/stricture (general anaesthesia) (eight requiring two or more procedures) 18.0% (31)
Bladder neck incision for stricture (one requiring two procedures) 10.5% (18)
Intervention for stricture/necrotic tissue by catheter type
Urethral 40.4% (38 out of 94)
Suprapubic 19.4% (13 out of 67)
(Pearson w
2,P¼0.005)
Urinary tract infection/dysuria 23.8% (41)
Epididymitis 7.6% (13)
Stress urinary incontinence (Grade 1) (no pads) 7.6% (13)
Stress urinary incontinence (Grade 3) 0.6% (1)
Recto-urethral fistulae 0% (0)
Potency
Using cohort of men who were potent pre-operatively on questionnaire and had filled in questionnaires at 3, 6, 9, and 12 months. Defined as scoring either 2 or 3 and
above on IIEF-15 question 2 ‘When you had erections with sexual stimulation, how often were your erections hard enough for penetration?’
Months 0 3 6 9 12
N (Score X2) 24/24 9/24 11/24 14/24 16/24
% (Score X2) 100 37.5 45.8 58.3 66.7
N (Score X3) 12/12 5/12 7/12 8/12 8/12
% (Score X3) 100 41.7 58.3 66.7 66.7
N 94 92 77 51 34
IIEF-15 Score 33.8 18.1 39.1 23.9 28.1
s.d. (22.16) (14.67) (22.09) (19.51) (21.46)
T-test (comparison with baseline (P-value)) NA o0.01 0.12 0.06 0.19
Mean IPSS Score 6.7 12.0 9.2 7.9 7.8
s.d. 5.84 8.60 8.00 7.51 7.33
T-test (comparison with baseline (P-value)) NA o0.01 0.02 0.32 0.42
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swere potent at 3, 6, 9, and 12 months, respectively. In the second
analysis, mean IIEF-15 scores at baseline and then at 3, 6, 9, and 12
months was 33.8, 18.1, 39.1, 23.9, and 28.1, respectively. A t-test
comparison showed a statistically significant drop in IIEF-15 score
at 3 months compared with baseline (Po0.01), but no significant
difference at other times compared with baseline (Table 2).
Cancer control outcomes
Figure 1 illustrates the PSA changes that occurred over the period
of follow-up with mean PSA levels at baseline, 3, 6, 9, 12, 18, and 24
months of 8.3ngml
 1 (range 7.01–9.41), 0.33 (range 0.22–0.45),
0.49 (range 0.28–0.69), 0.54 (range 0.26–0.82), 0.65 (range 0.27–
1.02), 0.68 (range 0.39–0.97) and 0.57 (range 0.12–1.02). The
proportion achieving PSA levels p0.2ngml
 1 for those who
completed 3, 6, 9, 12, 18, and 24 months was 70, 65, 58, 58, 57, and
60.9%, respectively (Table 3) (Figure 2). We found no significant
relationship between Gleason score, preoperative PSA, or T-stage
and the ability to render a PSA nadir p0.2ngml
 1 (univariate
analysis). In comparison 83, 78, 81, 78, 75, and 83% of men
achieved p0.5ngml
 1, at 3, 6, 9, 12, 18, and 24 months,
respectively (Figure 3). We analysed the effect of hormonal use
on the ability to achieve a PSA nadir o0.2 and o0.5ngml
 1 with
the use of Kaplan–Meier curves. There was no statistically
significant difference between the group on hormones and those
without (Breslow (Generalised Wilcoxon) P¼0.693 for PSA
0.2ngml
 1 and P¼0.146 for PSA 0.5ngml
 1) (Figures 4 and 5).
Of those achieving unrecordable PSA levels at 3 months follow-up,
23 out of 64 had hormones and 41 out of 64 had no hormones.
Not all men accepted post-HIFU biopsies, because those in
whom the PSA was 40.5ngml
 1 but stable did not wish to have
biopsies. Therefore, 31 patients were biopsied. 13 had proven
histological evidence of either residual or recurrent cancer. The
histology demonstrated Gleason score 7 in 5 out of 13 and Gleason
score 6 in 7 out of 13 (ungradeable in 1 out of 13). Of the 13 with
histological evidence of recurrent/residual cancer, eight opted for
re-treatment with HIFU. Of these, three out of eight had
biochemical control at 6–12 months (PSA o0.2ngml
 1 in two
out of eight and o0.5ngml
 1 in one out of eight), one out of eight
failed again (positive on biopsy) and underwent salvage external
beam radiotherapy and four out of eight had insufficient follow-up
to make meaningful comments about PSA kinetics (o6 months).
The remainder who had positive biopsies (5 out of 13) opted for
active surveillance of low volume, Gleason 3þ3 residual prostate
cancer. Figure 6A–C show a series of MRI scans demonstrating the
ablation that is possible in a successful HIFU treatment whereas
Figure 7A–C demonstrate incomplete ablation.
DISCUSSION
The natural history of prostate cancer prevents the use of mortality
as an outcome measure in most short- to medium-term reports of
prostate cancer therapy, so surrogates in the form of biochemical
failure have emerged. However, the optimal definition of
biochemical failure is far from clear. Indeed, owing to this lack
of certainty the reporting of minimally invasive modalities has
shown little consistency. The variability in biochemical outcome is
demonstrated by the differing PSA nadirs used to define a
successful outcome after cryosurgery or HIFU, with groups using
any one of PSA p1, p0.5, p0.4, p0.3, p0.2, and p0.1ngml
 1.
PSA nadir p0.2ngml
 1 has evidence within radical prostatectomy
series demonstrating its ability to predict a long-term outcome.
Evidence for this particular level is currently insufficient for HIFU
(Ganzer et al, 2008). A number of series use three successive PSA
rises to define treatment failure according to the previous
American Society for Therapeutic Radiology and Oncology
(ASTRO) criteria to define biochemical failure after radiotherapy
(ASTRO, 1997). This has its own drawbacks because the ASTRO
criteria are not appropriate for evaluating PSA elevations sooner
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Follow-up after HIFU treatment
Figure 1 PSA outcome for Localised Prostate Cancer Treated with HIFU.
Table 3 Biochemical and biopsy outcome for localised prostate cancer
treated with HIFU
Follow-up (months) 3 6 9 12 18 24
N 155 120 103 83 63 23
Biochemical parameters
PSA (ngml
 1)
o0.05
n 64 43 36 29 26 10
% 41.2 35.8 35.0 35.0 41.3 43.5
p0.2
n 108 78 60 48 36 14
% 69.7 65.0 58.3 57.8 57.1 60.9
p0.5
n 129 94 83 65 47 19
% 83.2 78.3 80.6 78.3 74.6 82.6
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sthan 3 years follow-up and were validated for radiotherapy.
Indeed, with the emergence of the ASTRO Phoenix criteria
(nadirþ2ngml
 1) (Roach et al, 2006), the old definition is in
itself questionable.
We have therefore chosen to report outcomes for three PSA
values. At present, none of these parameters have been validated
for HIFU or cryosurgery and for this reason we argue for their
inclusion. The unrecordable level allows some comparison to
radical prostatectomy in which this is achievable in the majority.
PSA p0.2ngml
 1 has some evidence to demonstrate that it may
be predictive of long-term cancer control following surgery and
possibly after HIFU (Cookson et al, 2007; Ganzer et al, 2008). PSA
p0.5ngml
 1 is an extra outcome measure that many ablative
therapy series use so its inclusion may be of pragmatic use to allow
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Figure 2 Kaplan Meier curve demonstrating Biochemical Progression
Free Survival (PSA o/¼ 0.2ng/ml) following whole-gland HIFU.
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Figure 3 Kaplan Meier curve demonstrating Biochemical Progression
Free Survival (PSA o/¼ 0.5ng/ml) following whole-gland HIFU.
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Figure 4 Kaplan Meier curve demonstrating the effect of hormone used
as cytoreduction prior to HIFU (PSA o/¼0.2ng/ml).
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Figure 5 Kaplan Meier curve demonstrating the effect of hormone used
as cytoreduction prior to HIFU (PSA o/¼0.5ng/ml).
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scomparison. Our early results demonstrate that the biochemical
outcome in the first 2 years is seen uniformly throughout all three
risk categories, although we accept that with greater follow-up
cancer control is likely to deteriorate in the high-risk groups. A
significant number in this series achieve early biochemical
outcomes equivalent to radical prostatectomy (more than one-
third achieve unrecordable PSA levels; 60% achieve p0.2ngml
 1).
Furthermore, approximately 80% treated in this manner were able
to achieve a PSA nadir of p0.5ngml
 1 within 3 months with this
percentage maintained up to 12 months.
The evidence base for HIFU is growing with medium and long-
term results now being reported. A total of 10 series have been
published to date. These include medium-term results (10–30
months follow-up) (Gelet et al, 2001; Chaussy and Thuroff, 2003;
Thuroff et al, 2003; Vallancien et al, 2004; Ficarra et al, 2006;
Uchida et al, 2006a,b; Poissonnier et al, 2007) and longer term
results (5 years or more) (Blana et al, 2004, 2008). Two have used
the Sonablate 500 and the remainder the Ablatherm. These series
include HIFU re-treatments within the overall outcome data with
mean HIFU sessions ranging from 1.17 to 1.4. In summary,
incontinence rates ranged from 0.5 to 15.4%, impotence 13–53%
and recto-urethral fistulae 0–2%. Biochemical control rates varied
from 66 to 84% (ASTRO criteria) at mean follow-up that varied
between 3 and 5 years. It is therefore encouraging that longer term
data are now emerging from HIFU cohort series. The distinction
between which series used which device is only of minor
importance.
We have demonstrated that a cohort of men comprising a wide
spectrum of risks can be treated with HIFU in a one-off, day-case
setting in a safe manner with good biochemical outcomes.
Although higher risk groups have been treated, it is important to
note that with limited follow-up, the poorer outcomes seen in
high-risk categories is likely to not have manifest itself. None-
theless, impotence is still significant. To reduce morbidity further,
focal therapy has been proposed as a paradigm shift in the
management of prostate cancer. HIFU could fulfil this role as it is
able to discretely ablate defined areas of tissue within the prostate
A
B
C
Figure 6 Contrast enhanced MRI changes in a successful treatment for
prostate cancer using HIFU. (A) 1.5 Tesla dynamic contrast enhanced MRI
using gadolinium prior to HIFU treatment demonstrating localised disease
with a lesion in the left antero-lateral side of the gland (circled). (B) 1.5
Tesla dynamic contrast enhanced MRI using gadolinium at 2 weeks
demonstrating poor perfusion in the prostate after HIFU treatment.
Urethral catheter seen in-situ. (C) 1.5 Tesla dynamic contrast enhanced
MRI using gadolinium at 6 months no residual prostate tissue and fibrotic
reaction.
A
B
C
Figure 7 Contrast enhanced MRI changes in an under-treated prostate
following HIFU. (A) 1.5 Tesla dynamic contrast enhanced MRI using
gadolinium prior to HIFU treatment demonstrating localised disease with a
lesion in the left postero-lateral side of the gland (circled). (B) 1.5 Tesla
dynamic contrast enhanced MRI using gadolinium at 2 weeks demonstrating
poor perfusion in the posterior prostate after HIFU treatment but an area
of residual tissue with enhancement anteriorly (circled). (C) 1.5 Tesla
dynamic contrast enhanced MRI using gadolinium at 6 months showing
residual prostate tissue (circled).
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s(Ahmed et al, 2007). Focal therapy trials are currently ongoing at
our centre and in a number of centres in the United States (Ahmed
and Emberton, 2007).
Before addressing the policy implications of these findings
certain important methodological considerations need to be
addressed. First, there is incomplete reporting of outcome. For
instance, whether men were evaluated by a questionnaire
depended on which site they were treated. We cannot be sure
that the same result would have arisen had all been tested. To assist
the reader we have tried to document both the numerator and
denominator so that the sample on which the variable is being
evaluated is made explicit.
Second, our evaluation of genito-urinary outcomes was limited.
Question 2 of the IIEF-15 does not assess whether there has been
any change in the quality of the erections. This is an acknowledged
clinimetric challenge (Burnett et al, 2007). We have attempted to
mitigate this by reporting total IIEF-15 scores for all men who
completed it at follow-up and using two thresholds for defining
potency on question 2.
Third, the early post-treatment toxicity deserves comment, as it
remains poorly understood. The rates we report are high and
challenge the claim of the treatment being both minimally invasive
and well tolerated. Infection and dysuria have been grouped
together. Many were assumed by us and primary care physicians to
be urinary tract infections and were treated as such, without
evidence of a positive urine culture. Patients are now told that they
should expect these symptoms. Having said this, the very high rate
of epididymo-orchitis was certainly of bacterial origin. Now that
suprapubic catheters are used combined with early removal, there
may be a reduction in this complication. The issue of retained
debris or stricture also deserves comment. If rates similar to those
reported in this paper had persisted we would not have wanted to
continue with this treatment. Most of the events were clustered to
the early part of the series at the beginning of our learning curve
and our threshold for intervention was very low. Any report of
difficulty in voiding led to cystoscopy. At present, we intervene
rarely and instruct the patients to self-catheterise if voiding is
impaired, with an inability to catheterise resulting in cystoscopy. It
is felt that self-catheterisation may aid in dislodging retained
debris causing an acute deterioration in urine flow. Whether such
a policy will result in fewer interventions, especially bladder neck
incision and dilatation for stricture, is yet to be proven. Therefore,
our early results clearly stand and it will be incumbent on
subsequent analyses to establish the true rate of these side-effects
in the most recent patients where our threshold for intervention
has changed.
Fourth, the use of hormones for cytoreduction will have resulted
in potential confounding. In all cases this was in the form of an
antiandrogen with or without a 5 a-reductase inhibitor for 3
months. These were stopped on the day of the procedure.
Dutasteride and finasteride have a half-life of 5–6 weeks and
5–8h, respectively. Bicalutamide has a half-life of 6 days. We
therefore argue that the influence of these hormonal agents would
have been minimal by 3 months and virtually absent by 6 months.
This assumption is supported by Kaplan–Meier curves which
demonstrate no statistically significant difference between those
taking hormones and those without (Figures 4 and 5).
Fifth, given the absence of formal exclusion/inclusion criteria it
was inevitable that some key baseline data would not be available
for analysis. Again, to mitigate this, we have not sought to exclude
the latter group and have reported outcomes for all men. There
was no difference in biochemical or histological outcome between
those with full data that permitted D’amico risk stratification and
those in whom it was not possible.
Sixth, the absence of systematic evaluation probably has the
greatest impact on the way in which the status of presence or
absence of disease was elicited from the treated prostate. In other
words, it was only those in whom the PSA rose above 0.5ngml
 1
or those in whom a rising PSA was seen were advised to have a
biopsy. Only those who agreed to have this done could be
evaluated. The inclusion of standard biopsies may have explained
why the 3 months median PSA rises from 0.33ngml
 1 at 3 months
to 0.57 at 24 months. It is difficult to explain this. One could
speculate that in a similar vain to prostate brachytherapy in which
a ‘PSA bounce’ occurs between 1 and 3 years and can be as high as
2ngml
 1 although the mean bounce is around 0.5ngml
 1. The
mechanism of tissue ablation is very different to brachytherapy so
it is not immediately clear if and why such a bounce should occur.
The increase may also represent an early sign of failure. However,
with smaller numbers at 24 months follow-up it is difficult to
ascertain whether this increase in PSA is a sustained one. Within a
trial setting for a novel therapy the requirement for patients to
undergo a protocol biopsy would be the standard. However, whole-
gland HIFU used in the way described in this paper is not new and
it was approved in the United Kingdom as a therapeutic alternative
with the requirement for close follow-up by NICE. Therefore, the
elicitation of the histological status was conditional on absolute
PSA values or PSA kinetics. The bias that might result from this
approach is an underestimation of residual or recurrent prostate
cancer.
CONCLUSIONS
HIFU in the treatment of prostate cancer can result in acceptable
short-term levels of cancer control. Moreover, it can be used with a
high degree of certainty that the man will remain continent
afterwards and two-thirds might expect to have erections sufficient
for penetration 1 year following treatment. Importantly for some,
this can be achieved in a one-off treatment in an ambulatory
setting with the majority discharged home the same day after a few
hours. Nonetheless, our data remains immature and the determi-
nants of outcome are not yet known. Clearly, longer term follow-
up is required, but in a more systematic and prospective manner.
The difficulty in recruiting to randomised controlled studies when
comparing treatments for prostate cancer has been demonstrated
with the latest cryosurgery vs radiotherapy randomised controlled
trial that failed to recruit (Donnelly et al, 2007). As in other areas
of emerging technology the most efficient and effective way to
collect long-term prospective data may be through an online
registry (McCulloch et al, 2002; Grilli and Taroni, 2006). Although,
the recent NICE guidelines in the United Kingdom (Graham et al,
2008) have recommended HIFU as well as cryosurgery be used
only if patient data are added prospectively into clinical trials, their
implementation guidelines have clarified that national or interna-
tional registries are also acceptable (NICE Implementation advice
on Prostate Cancer Guidelines, 2008). The British Association of
Urological Surgeons have followed suit on this advice and have
opened their cancer registry to all cryosurgery and HIFU
treatments for prostate cancer. There are industry-sponsored
international registries for HIFU and cryosurgery already set up
(Jones et al, 2008). Such registries must ensure impartiality with
strict guidelines and data monitoring to ensure the data is a true
representation of real practise. This should ensure that the lack of
comparative data does not inhibit the timely diffusion of
potentially successful technologies into mainstream clinical
practise for the benefit of men undergoing treatment for prostate
cancer.
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